Clinical Scorecard: Semaglutide Reduced Nicotine Craving in Small Trial
At a Glance
| Category | Detail |
|---|---|
| Condition | Nicotine Craving in Daily Smokers |
| Key Mechanisms | Semaglutide, a glucagon-like peptide-1 receptor agonist, was evaluated for its effects on nicotine craving and body weight. |
| Target Population | Non-treatment-seeking adults who smoke at least 5 cigarettes daily. |
| Care Setting | Phase 2a randomized clinical trial. |
Key Highlights
- Semaglutide led to greater reductions in nicotine craving compared to placebo.
- Participants receiving semaglutide lost about 5% of body weight.
- No significant difference in cigarettes smoked per day between groups.
- Most adverse events were mild, primarily gastrointestinal effects.
- The study was limited by a small sample size and short duration.
Guideline-Based Recommendations
Diagnosis
- Participants were required to smoke at least 5 cigarettes daily.
Management
- Semaglutide was administered weekly, escalating from 0.25 mg to 0.5 mg, with a 1.0 mg dose when tolerated.
Monitoring & Follow-up
- Monitor nicotine craving, body weight, and hemoglobin A1c levels.
Risks
- Mild gastrointestinal adverse events were noted, with one participant discontinuing due to adverse events.
Patient & Prescribing Data
Adults who smoke daily and are not actively seeking treatment for smoking cessation.
Semaglutide may reduce nicotine craving and body weight but does not significantly impact smoking behavior.
Clinical Best Practices
- Consider the limited applicability of findings to smokers actively trying to quit.
- Evaluate the potential for semaglutide in managing nicotine cravings in non-treatment-seeking populations.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
